Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972


Spotlight on Scrip Perspectives 24/25


Focus On Asia


Data Analysis


R&D


Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.

Does Shingrix Really Lower Dementia Risk? GSK Funds Real World Research To Verify

 

A new “quasi-experimental” study using UK National Health Service data might confirm that GSK’s shingles vaccine helps cut dementia cases.

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By 

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

Deloitte Sees Rising Industry ROI, But Challenge In Sustaining It

 
• By 

Projected return on investment for the 20 pharmas with the highest R&D spend is expected to rise for the second straight year, Deloitte says. How to get there is less clear.

Business


Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset

 
• By 

Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By 

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Scrip Originals


Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By 

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Pipeline Watch: Nine Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Finance Watch: Cargo Restructuring Not The News The IPO Market Needs

 
• By 

Public Company Edition: Cargo suspended development and cut 90% of its workforce to focus on strategic alternatives, while Pyxis and Kiromic laid off or furloughed employees. Also, Pfizer sold its remaining Haleon shares for $3.3bn, Galderma sold $1bn in bonds and other financings.

Finance Watch: Venture Capital Mega-Rounds Attempt A Rebound In March

 
• By 

Private Company Edition: There have been five $100m-plus VC rounds so far this month, up from three in all of February. Flagship unveiled Lila Sciences with $200m, while Curevo and Insilico raised $110m in series B and E rounds, respectively. Also, Arbor Biotech garnered $73.9m.